16-peptide signature.

<p>Relative importance of the contribution of each peptide in the 16-peptide multivariate signature for differentiating AD vs. NL that is subsequently used for predicting progression of MCI subjects to AD. Peptides are plotted in the order of their importance/contribution to this multivariate signature in the logistic regression model. As the 16^th peptide related to CATD appears to provide very little incremental value (noted in red), the data-driven process that led to its inclusion in the signature suggested an overall benefit of retaining it in the signature. The coefficients for each of these markers is given in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182098#pone.0182098.s002" target="_blank">S2 Table</a>.</p

Normal vs. Alzheimer Disease, univariate analysis.

<p>Shown are the analytes with a q-value < 0.05.</p

Three-year MCI converter vs. nonconverter demographics.

<p>Three-year MCI converter vs. nonconverter demographics.</p

MCI to AD converters vs. non-converters, univariate analysis, lowest 20 q-values.

<p>MCI to AD converters vs. non-converters, univariate analysis, lowest 20 q-values.</p

Performance of multivariate model to differentiate disease state.

<p>The top row corresponds to all permutations of Ab, tTau and pTau, and the bottom row refers to the 16-peptide signature shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0182098#pone.0182098.g002" target="_blank">Fig 2</a>.</p

Kaplan-Meier curves.

<p>A) Kaplan-Meier curves over the entire time course until the last follow-up visit that show the relative rates of future progression to AD for the MCI subjects identified as signature positive or negative at baseline by the 16-peptide multivariate signature. B) Similar curves, but for subjects that were identified as signature positive or negative by the Aβ/t-Tau/p-Tau biomarkers. MTP = mean time to progression.</p

Disease-state demographics.

<p>Disease-state demographics.</p

Performance of AD vs. NL multivariate signatures to differentiate the Time to Progression of MCI subjects to AD.

<p>Performance of AD vs. NL multivariate signatures to differentiate the Time to Progression of MCI subjects to AD.</p

Receiver-operator curves.

<p>Receiver-operator curves comparing the 16-peptide multivariate signature (red dotted line) to combinations of Aβ42, tau and p-tau 181 (black line) as well as the 16-peptide signature + combinations of Aβ42, tau and p-tau 181 (blue dashed line) for the prediction of 36-month conversion from MCI to AD.</p